HIRA decides Keytruda & Opdivo’s insurance benefits with anti-PD-L1 TPS
‘Tumor proportion score(TPS) of anti-PD-L1’ is set as an index to decide whether to accept the insurance benefits of immunotherapies to treat non-small cell lung cancer.
The health insurance benefits of MSD’s ‘Keytruda(generic name: pembrolizumab)’ and Ono Pharmaceutical’s Opdivo(generic name: ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
